Home > Boards > US OTC > Biotechs > NorthWest Biotherapeutics Inc. (NWBO)

MALT1 in glioblastoma

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
abeta Member Profile
Member Level 
Followed By 21
Posts 2,213
Boards Moderated 0
Alias Born 02/06/17
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/16/2020 6:59:18 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 10/13/2020 9:31:10 AM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 9/15/2020 5:14:31 PM
SA Breaking News: ALYI - Alternet Systems revenue surging with new potential customers InvestorsHub NewsWire - 9/14/2020 10:10:04 AM
Traders News Source Identifies Tomorrows NASDAQ's InvestorsHub NewsWire - 9/3/2020 8:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/1/2020 3:24:29 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/20/2020 4:52:41 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/10/2020 4:44:16 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/7/2020 5:27:35 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/26/2020 5:07:03 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 6/24/2020 6:02:25 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/8/2020 5:02:02 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/4/2020 5:12:40 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/29/2020 5:28:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/27/2020 5:15:15 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/20/2020 5:06:06 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 5/12/2020 4:12:38 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/23/2020 5:10:20 PM
Cannabis? CBD? That's Old News, A New Sector Bull Run Has Begun InvestorsHub NewsWire - 4/16/2020 8:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 4/9/2020 5:28:45 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/1/2020 4:41:56 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 3/27/2020 2:47:39 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/16/2020 5:01:48 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 2/24/2020 5:07:15 PM
PURA ALERT - MACD Cross Pushing $0.039 50 Day MA With $0.35 Analyst TGT Recommendation InvestorsHub NewsWire - 2/10/2020 12:50:46 PM
abeta Member Level  Monday, 09/07/20 10:34:23 AM
Re: None
Post # of 322799 
MALT1 in glioblastoma

Nov - 2019

Quote:
indicated that low MALT1 levels strictly correlated with patients’ survival in brain cancer. Adding MALT1 blockers to cell cultures of glioblastoma stem cells, caused the self-renewing tumour cells to undergo a rare form of cellular suicide termed lysosomal cell death. In further analyses, it turned out that MALT1 keeps lysosomes low in cancer cells, which is crucial for their survival. In contrast, both, blocking MALT1 genetically and pharmacologically led to an increase in lysosomes, which in turn impaired the cells’ waste disposal system, eventually killing them. The findings in cell culture have already be validated in animal models.

However, MALT1 blockers such as the former tranquilizer mepazine, a drug of the 1960ies, have shown adverse side effects. Even though, development activity of MALT-1 inhibitors have been revived. Janssen Research & Development, LLC is in Phase I testing of a MALT1 blocker code-named JNJ-67856633 in Non-Hodgin lymphoma.

Gavard and colleagues recommend development of repurposed MALT-1 blockers to treat glioblastoma.



https://european-biotechnology.com/up-to-date/latest-news/news/researchers-find-new-indication-for-cancer-drug.html


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences